Affordable Access

Publisher Website

Clinical and histopathological predictors of outcome in malignant meningioma.

Authors
  • Maier, Andrea D1
  • Bartek, Jiri Jr2, 3, 4
  • Eriksson, Frank5
  • Ugleholdt, Heidi6
  • Juhler, Marianne2
  • Broholm, Helle6
  • Mathiesen, Tiit I4, 7
  • 1 Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. [email protected]. , (Denmark)
  • 2 Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. , (Denmark)
  • 3 Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden. , (Sweden)
  • 4 Department of Clinical Neuroscience and Department of Medicine, Karolinska Institutet, Stockholm, Sweden. , (Sweden)
  • 5 Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. , (Denmark)
  • 6 Department of Pathology, Center of Diagnostic Investigation, Copenhagen University Hospital, Copenhagen, Denmark. , (Denmark)
  • 7 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. , (Denmark)
Type
Published Article
Journal
Neurosurgical review
Publication Date
Apr 01, 2020
Volume
43
Issue
2
Pages
643–653
Identifiers
DOI: 10.1007/s10143-019-01093-5
PMID: 30868425
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7-150.7). The median progression-free survival was 16.5 months (95% CI 11.4-43.0) and the median overall survival was 46.6 months (95% CI 20.4-NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10% was a negative predictor of PFS (HR 3.92, 95% CI 1.47-10.4, p = 0.0063) and OS (HR 3.35, 95% CI 1.12-10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95% 1.32-15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10% correlated with PFS and OS within grade III tumors.

Report this publication

Statistics

Seen <100 times